A Multicentre Randomised Placebo-Controlled Double-Blind Pivotal Clinical Trial for the Evaluation of Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-Adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen rBet v 1-FV.

Trial Profile

A Multicentre Randomised Placebo-Controlled Double-Blind Pivotal Clinical Trial for the Evaluation of Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-Adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen rBet v 1-FV.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2013

At a glance

  • Drugs Birch pollen allergy immunotherapy (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 14 Nov 2012 Planned number of patients changed from 800 to 835 as reported by European Clinical Trials Database record.
    • 14 Oct 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 30 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top